{"analyses":[{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.14","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.20","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalMethod":"stratified Cox PH model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.55","upperLimit":"28.94","value":"24.48"},{"groupId":"OG001","lowerLimit":"19.61","upperLimit":"25.53","value":"23.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"description":"OS is defined as time to death for any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT could be used.","id":"OG000","title":"177Lu-PSMA-617 (AAA617)"},{"description":"For participants randomized to the ARDT arm, the change of ARDT treatment was administered per the physician's orders. Best supportive care, including ADT could be used.","id":"OG001","title":"Androgen Receptor-directed Therapy (ARDT)"}],"paramType":"MEDIAN","populationDescription":"FAS comprised all participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"approx. 26.9 months from randomization to cut-off","title":"Overall Survival (OS) (Key Secondary Endpoint)","type":"SECONDARY","unitOfMeasure":"months"}